Victor L. L. Villemagne
#127,544
Most Influential Person Now
Victor L. L. Villemagne's AcademicInfluence.com Rankings
Victor L. L. Villemagnephilosophy Degrees
Philosophy
#6036
World Rank
#8998
Historical Rank
Logic
#3230
World Rank
#4356
Historical Rank

Victor L. L. Villemagnebiology Degrees
Biology
#8179
World Rank
#11216
Historical Rank
Neuroscience
#1116
World Rank
#1158
Historical Rank

Download Badge
Philosophy Biology
Victor L. L. Villemagne's Degrees
- PhD Neuroscience University of Melbourne
- Doctorate Medicine University of Melbourne
Why Is Victor L. L. Villemagne Influential?
(Suggest an Edit or Addition)Victor L. L. Villemagne's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study (2013) (1546)
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease (2018) (969)
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (2010) (950)
- Activation of memory circuits during cue-elicited cocaine craving. (1996) (921)
- β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease (2007) (719)
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease (2011) (718)
- The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease (2009) (680)
- Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism (2008) (634)
- Imaging β-amyloid burden in aging and dementia (2007) (610)
- Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. (2015) (476)
- Tau imaging: early progress and future directions (2015) (435)
- Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. (2007) (409)
- Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography (2008) (401)
- Relationship between atrophy and β‐amyloid deposition in Alzheimer disease (2010) (354)
- Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
- Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. (2011) (304)
- Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment (2014) (289)
- 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. (2011) (280)
- Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias (2011) (278)
- Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease (2008) (272)
- Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease (2013) (270)
- Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions (2018) (266)
- Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease (2007) (255)
- Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. (2012) (244)
- Combined PET/CT Imaging in Oncology. Impact on Patient Management. (2000) (237)
- Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease (2013) (235)
- β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia (2010) (232)
- Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. (2014) (228)
- Suspected non-Alzheimer disease pathophysiology — concept and controversy (2016) (224)
- Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics (2006) (221)
- The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies (2009) (214)
- Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing (2013) (207)
- Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (2013) (198)
- Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations (2013) (198)
- High performance plasma amyloid-beta biomarkers for Alzheimer's disease (2018) (197)
- Brain Amyloid Imaging (2011) (191)
- Cerebral quantitative susceptibility mapping predicts amyloid-&bgr;-related cognitive decline (2017) (185)
- The Amyloid-β Pathway in Alzheimer’s Disease (2021) (185)
- Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. (2014) (183)
- Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study (2016) (182)
- Plasma apolipoprotein E and Alzheimer disease risk (2011) (182)
- Image Analysis in Patients with Cancer Studied with a Combined PET and CT Scanner (2000) (180)
- Fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment (2018) (177)
- Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease (2012) (175)
- In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease (2014) (167)
- High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. (2009) (163)
- Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias (2020) (163)
- Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition (2012) (163)
- Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. (2013) (162)
- In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies (2007) (159)
- Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study (2011) (153)
- Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. (2015) (151)
- 11C-PIB binding is increased in patients with cerebral amyloid angiopathy–related hemorrhage (2010) (149)
- Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) (145)
- Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. (2011) (142)
- Larger temporal volume in elderly with high versus low beta-amyloid deposition. (2010) (140)
- Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts (2018) (140)
- Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia (2013) (138)
- The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease (2012) (136)
- Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age (2013) (136)
- Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. (2010) (125)
- Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease (2019) (123)
- Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease (2016) (121)
- Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease (2011) (121)
- Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease (2014) (121)
- Incidence of cerebral microbleeds in preclinical Alzheimer disease (2014) (120)
- Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology (2018) (118)
- In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 (2010) (116)
- Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
- Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease (2020) (115)
- Four-repeat tauopathies (2019) (115)
- APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease (2014) (113)
- A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study (2014) (110)
- Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults (2012) (109)
- Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals (2017) (109)
- Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia (2018) (107)
- Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias (2009) (106)
- In vivo tau imaging: Obstacles and progress (2014) (106)
- BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease (2013) (105)
- The Relationship between Sleep Quality and Brain Amyloid Burden. (2016) (100)
- Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data (2013) (99)
- Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease (2014) (98)
- The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias (2008) (97)
- Comparison of MR-less PiB SUVR quantification methods (2015) (97)
- In Vivo Measurement of Dopamine Receptors in Human Brain by Positron Emission Tomography Age and Sex Differences a (1988) (97)
- Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy (2020) (94)
- Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study (2014) (93)
- Localization of serotonin 5‐HT2 receptors in living human brain by positron emission tomography using N1‐([11C]‐methyl)‐2‐BR‐LSD (1987) (93)
- Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET (2017) (91)
- Aβ-amyloid and Tau Imaging in Dementia. (2017) (90)
- Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. (2011) (88)
- Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). (2013) (88)
- Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture (2020) (86)
- Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study (2014) (86)
- The challenges of tau imaging (2012) (86)
- Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. (2007) (86)
- In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. (2009) (85)
- Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging (2008) (80)
- Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies (2018) (79)
- Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease (2014) (79)
- Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques. (2013) (78)
- In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106 (2013) (77)
- 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids (2017) (77)
- Radiation Dosimetry of β-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 (2009) (76)
- Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease (2010) (76)
- Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (2015) (75)
- Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples (2013) (74)
- Radioiodinated clioquinol as a biomarker for β‐amyloid: Zn2+ complexes in Alzheimer's disease (2006) (74)
- Evaluating image reconstruction methods for tumor detection in 3-dimensional whole-body PET oncology imaging. (2003) (74)
- Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies (2014) (74)
- Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score (2015) (72)
- Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden (2018) (72)
- Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. (1999) (69)
- 11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease (2009) (68)
- APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease (2015) (67)
- An increased neutrophil–lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation (2014) (67)
- Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale (2016) (66)
- Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease (2013) (66)
- Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study. (2011) (64)
- Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. (2016) (63)
- Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions (2016) (63)
- Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis (2020) (62)
- Association of &bgr;-Amyloid and Apolipoprotein E &egr;4 With Memory Decline in Preclinical Alzheimer Disease (2018) (61)
- Brain amyloid imaging. (2013) (61)
- Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. (2010) (60)
- Influence of BDNF Val66Met on the relationship between physical activity and brain volume (2014) (60)
- Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. (2014) (59)
- Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. (1997) (59)
- A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease (2019) (59)
- The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. (2006) (58)
- Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? (2014) (58)
- Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease (2019) (57)
- Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative (2010) (57)
- Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. (1997) (57)
- A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques. (2010) (56)
- Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease: A 2-[18F]fluoro-A-85380 PET study (2008) (55)
- Amyloid burden and incident depressive symptoms in cognitively normal older adults (2017) (55)
- Amyloid imaging with PET in early Alzheimer disease diagnosis. (2013) (55)
- A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study (2017) (54)
- Rapid decline in episodic memory in healthy older adults with high amyloid-β. (2013) (53)
- Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease (2005) (53)
- An analytic study of the effects of attenuation on tumor detection in whole-body PET oncology imaging. (2003) (52)
- Aβ amyloid, cognition, and APOE genotype in healthy older adults (2013) (52)
- 18F-florbetaben Aβ imaging in mild cognitive impairment (2013) (52)
- Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
- Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
- MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET (2014) (51)
- In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. (2012) (50)
- [125/123I]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors (1997) (49)
- Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. (2011) (49)
- Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. (2017) (49)
- Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. (2015) (48)
- Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods (2018) (47)
- Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. (2013) (47)
- Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease (2017) (47)
- Relationship between Memory Performance and β-Amyloid Deposition at Different Stages of Alzheimer’s Disease (2012) (46)
- 18 F-THK 523 : a novel in vivo tau imaging ligand for Alzheimer ’ s disease (2011) (46)
- Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials (2013) (46)
- Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (46)
- Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease (2020) (45)
- Clinical Profile of PiB-Positive Corticobasal Syndrome (2013) (45)
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
- Intravenous Nicotine Reduces Cerebral Glucose Metabolism: A Preliminary Study (2003) (44)
- Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD (2019) (44)
- Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI. (2015) (44)
- Amyloid imaging: Past, present and future perspectives (2016) (43)
- Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults (2017) (43)
- Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. (2005) (43)
- Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using F-THK5105 PET (2014) (43)
- Engineered antibodies: new possibilities for brain PET? (2019) (42)
- Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. (2015) (42)
- Decline in cognitive function over 18 months in healthy older adults with high amyloid-β. (2013) (42)
- Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease (2016) (41)
- Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging (2012) (41)
- Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease (2021) (41)
- Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease (2020) (41)
- Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. (2015) (41)
- Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2020) (41)
- Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. (2014) (40)
- Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (2018) (40)
- Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes (2017) (40)
- b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease (2007) (39)
- Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease (2021) (39)
- Risk of Alzheimer's Disease in Obstructive Sleep Apnea Syndrome: Amyloid-β and Tau Imaging. (2018) (39)
- Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. (2011) (38)
- Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. (2012) (38)
- Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology (2019) (37)
- A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease (2016) (37)
- MR atlas of the baboon brain for functional neuroimaging (2002) (37)
- Subacute Ischemic Stroke Is Associated With Focal 11C PiB Positron Emission Tomography Retention But Not With Global Neocortical A&bgr; Deposition (2012) (36)
- Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests. (2012) (36)
- Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) (2013) (36)
- Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months (2015) (36)
- In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. (2011) (36)
- In vivo labeling of the dopamine D2 receptor with N-11C-methyl-benperidol. (1990) (36)
- Differentiating the frontal presentation of Alzheimer's disease with FDG-PET. (2015) (36)
- Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pathology. (2016) (35)
- The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (2016) (35)
- Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging (2015) (34)
- OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET (2016) (34)
- Long night's journey into the day: amyloid-β imaging in Alzheimer's disease. (2012) (34)
- Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. (2013) (34)
- Cerebral β‐amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator‐related hemorrhage (2010) (33)
- Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging (2015) (32)
- Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. (2017) (32)
- [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia (2017) (31)
- Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study (2014) (30)
- Imaging histamine H1 receptors in the living human brain with carbon-11-pyrilamine. (1991) (30)
- Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial (2020) (29)
- Neuroimaging biomarkers in Alzheimer’s disease and other dementias (2016) (29)
- KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden (2018) (29)
- A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer’s Disease (2017) (29)
- Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease? (2013) (29)
- Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort (2017) (29)
- Amyloid Imaging in Alzheimer’s Disease and Other Dementias (2009) (28)
- The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI (2013) (28)
- Predicting Alzheimer disease from a blood-based biomarker profile (2016) (28)
- Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury (2020) (28)
- Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease (2020) (28)
- Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation (2020) (27)
- Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β. (2018) (26)
- Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform (2014) (25)
- Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals (2020) (25)
- Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. (2018) (25)
- Automated (11)C-PiB standardized uptake value ratio. (2008) (25)
- Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET (2008) (25)
- Amyloid-β: the seeds of darkness. (2011) (24)
- Brain glucose metabolism in Rett Syndrome. (2002) (24)
- Dopamine transporter changes in neuropsychiatric disorders. (1998) (24)
- Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. (2018) (24)
- Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness (2017) (24)
- Cortical [18F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes (2021) (24)
- Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. (2002) (24)
- RETINAL AMYLOID FLUORESCENCE IMAGING PREDICTS CEREBRAL AMYLOID BURDEN AND ALZHEIMER'S DISEASE (2014) (23)
- Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study (2019) (23)
- Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. (2013) (23)
- Positron Emission Tomographic Imaging in Stroke (2015) (23)
- 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias (2015) (23)
- Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging (2020) (23)
- MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients (2008) (23)
- Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle? (2012) (23)
- Amyloid PET Ligands for Dementia. (2010) (22)
- Relationship between amyloid and tau levels and its impact on tau spreading (2021) (22)
- Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. (2017) (22)
- Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis (2016) (22)
- A&bgr;-related memory decline in APOE &egr;4 noncarriers: Implications for Alzheimer disease (2016) (22)
- Cerebral Blood Flow and Aβ-Amyloid Estimates by WARM Analysis of [11C]PiB Uptake Distinguish among and between Neurodegenerative Disorders and Aging (2017) (21)
- Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition (2020) (21)
- Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer’s disease (2018) (21)
- A ‘Disease Severity Index’ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia (2017) (21)
- PET studies of cerebral glucose metabolism: acute effects of cocaine and long-term deficits in brains of drug abusers. (1996) (21)
- A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort (2017) (21)
- Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects (2021) (21)
- Klotho allele status is not associated with Aβ and APOE ε4–related cognitive decline in preclinical Alzheimer's disease (2019) (21)
- Trajectories of depressive and anxiety symptoms in older adults: a 6‐year prospective cohort study (2018) (20)
- 18 F-florbetaben Ab imaging in mild cognitive impairment (2013) (20)
- BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF (2017) (19)
- Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. (2020) (19)
- Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. (2018) (19)
- Radiolabeled neuronal nitric oxide synthase inhibitors: synthesis, in vivo evaluation, and primate PET studies. (2000) (18)
- Positron Emission Tomographic Imaging in Stroke Cross-Sectional and Follow-Up Assessment of Amyloid in Ischemic Stroke (2015) (18)
- Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux. (2018) (18)
- Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease (2020) (18)
- β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. (2016) (18)
- Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease (2021) (17)
- Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. (2018) (17)
- Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults (2020) (17)
- Advances in Brain Amyloid Imaging. (2021) (17)
- Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET (2021) (17)
- A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer’s Disease (2018) (17)
- Computational analysis of PET by AIBL (CapAIBL): a cloud-based processing pipeline for the quantification of PET images (2015) (16)
- The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update (2021) (16)
- Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study. (2020) (16)
- Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease. (2015) (16)
- Peptide T and glucose metabolism in AIDS dementia complex. (1996) (16)
- Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults. (2018) (16)
- Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: An update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study (2013) (16)
- Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. (2011) (16)
- Rhenium and technetium complexes that bind to amyloid-β plaques. (2015) (16)
- Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease (2022) (16)
- Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology (2020) (16)
- In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data (2020) (15)
- The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain (2017) (15)
- Constructing longitudinal disease progression curves using sparse, short‐term individual data with an application to Alzheimer's disease (2017) (15)
- Rates of age- and amyloid β-associated cortical atrophy in older adults with superior memory performance (2019) (15)
- Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease. (2019) (15)
- Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients (2018) (15)
- Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease (2020) (15)
- 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. (2010) (15)
- Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET (2017) (15)
- Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia (2016) (14)
- Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study (2019) (14)
- Radiation Dosimetry of b-Amyloid Tracers 11 C-PiB and 18 F-BAY94-9172 (2009) (14)
- OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET (2016) (14)
- Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults. (2019) (14)
- Molecular Imaging Approaches in Dementia. (2021) (14)
- Tau deposition patterns are associated with functional connectivity in primary tauopathies (2022) (14)
- Alzheimer disease: The landscape of ageing—insights from AD imaging markers (2014) (14)
- Advances in molecular imaging for the diagnosis of dementia. (2009) (14)
- Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition (2019) (14)
- What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies (2020) (14)
- Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study (2021) (13)
- Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. (2018) (13)
- Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals (2020) (13)
- Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy (2021) (13)
- The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease (2005) (13)
- Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player (2020) (13)
- Effect of BDNF Val 66 Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer ’ s Disease : A Preliminary Study (2014) (13)
- [18F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment (2019) (13)
- Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease (2018) (12)
- PIB-PET SEGMENTATION FOR AUTOMATIC SUVR NORMALISATION WITHOUT MR INFORMATION (2007) (12)
- [125]I-spectramide: a novel benzamide displaying potent and selective effects at the D2 dopamine receptor. (1989) (12)
- Relationship between Atrophy and Beta-Amyloid Deposition in Normal Elderly, Mild Cognitive Impairment and Alzheimer's Disease (2010) (12)
- Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study (2019) (12)
- Targeting metals rescues the phenotype in an animal model of tauopathy. (2018) (12)
- Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-β Plaques. (2016) (12)
- La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease (2006) (12)
- Chronic stress and Alzheimer's disease: the interplay between the hypothalamic–pituitary–adrenal axis, genetics and microglia (2021) (12)
- Longitudinal evaluation of the natural history of amyloid-β in plasma and brain (2020) (12)
- Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. (2022) (12)
- Comparison of [11C]diprenorphine and [11C]carfentanil in vivo binding to opiate receptors in man using a dual detector system. (1994) (11)
- Automatic detection of small spherical lesions using multiscale approach in 3D medical images (2013) (11)
- Tractographic Threshold-Free Cluster Enhancement : Whole-Brain Statistical Analysis of Diffusion MRI Measures in the Presence of Crossing Fibres (2012) (11)
- IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA. Authors' reply (2008) (11)
- Aβ-related memory decline in APOE ε4 noncarriers (2016) (11)
- Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
- The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults (2018) (10)
- Early detection of amyloid load using 18F-florbetaben PET (2021) (10)
- Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI (2021) (10)
- Spline Based Inhomogeneity Correction for 11C-PIB PET Segmentation Using Expectation Maximization (2007) (9)
- Tau imaging with PET: an overview of challenges, current progress, and future applications. (2017) (9)
- CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method (2016) (9)
- A beta-amyloid and Tau Imaging in Dementia (2017) (9)
- Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation (2011) (9)
- The Aβcentric Pathway of Alzheimer’s Disease (2007) (9)
- Research and applications: MilxXplore: a web-based system to explore large imaging datasets (2013) (9)
- Amyloid imaging in therapeutic trials: The quest for the optimal reference region (2015) (9)
- Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease (2022) (9)
- Sensitivity of a Preclinical Alzheimer’s Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer’s disease (2019) (9)
- AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON THE BRAIN SURFACE (2019) (9)
- Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients (2018) (9)
- In vivo tau imaging in Alzheimer's disease and other dementias (2012) (8)
- Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease (2020) (8)
- Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults (2014) (8)
- Voyage au bout de la nuit: Aβ and tau imaging in dementias. (2014) (8)
- APOEɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. (2017) (8)
- Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease (2021) (8)
- Imaging of Reactive Astrogliosis by Positron Emission Tomography (2022) (7)
- Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer’s Disease (2020) (7)
- The exception makes the rule (2012) (7)
- Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism (2020) (7)
- EVALUATION OF [F-18]-PI-2620, A SECOND-GENERATION SELECTIVE TAU TRACER, FOR THE ASSESSMENT OF ALZHEIMER’S AND NON-ALZHEIMER’S TAUOPATHIES (2018) (7)
- Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum (2022) (7)
- AIBL (Australian Imaging, Biomarkers and Lifestyle) flagship study of aging (2009) (7)
- Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions (2018) (7)
- In vivo microstructural heterogeneity of white matter lesions in Alzheimer’s disease using tissue compositional analysis of diffusion MRI data (2019) (7)
- Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies (2020) (7)
- Imago Mundi, Imago AD, Imago ADNI (2014) (7)
- Assessment of Aβ Deposition in Mild Cognitive Impairment with 18F-Florbetaben (2010) (7)
- Safety of Disclosing Amyloid Imaging Results to MCI and AD Patients (2017) (7)
- PREDICTING ALZHEIMER'S DISEASE FROM A BLOOD-BASED BIOMARKER PROFILE: RESULTS FROM AIPL AT 54 MONTHS (2014) (7)
- II.P13 Amyloid load in Parkinson's Disease Dementia (PDD) and Lewy Body Dementia (LBD) measured with 11C-PIB PET (2006) (7)
- Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
- Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study (2021) (6)
- Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer’s Disease Patients and Correlates with Cognitive Performance (2020) (6)
- Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (6)
- FDG-PET: A sensitive tool for the localization of MIBG-negative pelvic pheochromocytomas (1998) (6)
- Age dependent prevalence of beta-amyloid positive 11C-PiB PET in healthy elderly subjects parallels neuropathology findings (2008) (6)
- Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing (2020) (6)
- Advances in structural and molecular neuroimaging in Alzheimer's disease (2011) (6)
- D2 DOPAMINE RECEPTORS IN TOURETTEʼS SYNDROME AND MANIC DEPRESSIVE ILLNESS (1988) (6)
- Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort (2022) (6)
- APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies (2022) (6)
- A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials (2019) (6)
- A simple probe measures the pharmacokinetics of[125I]RTI-55 in mouse brain in vivo. (1997) (6)
- Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
- Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: Predictive value of Aβ imaging with 18F-Florbetaben (2011) (6)
- 18F-Florbetaben (FBB) PET SUVR quantification: Which reference region? (2015) (6)
- Head-to-head comparison of 11C-PiB and 18F-AZD4694 for beta-amyloid imaging in aging and dementia (2012) (5)
- Effects of attenuation correction on tumor detection in PET oncology (2000) (5)
- PET Imaging of brain muscarinic receptors with 18F-Fluorobenzyl-Dexetimide: A first in human study (2021) (5)
- Amyloid-β, Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder. (2019) (5)
- Not all A plaques are created equal (2012) (5)
- COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults (2019) (5)
- First results from human studies of a novel F-18 PET ligand for brain {beta}-amyloid imaging (2007) (5)
- A head-to-head comparison of cerebral blood flow SPECT and 18 F-FDG PET in the diagnosis of Alzheimer's Disease. (2020) (5)
- Self-reported confusion is related to global and regional β-amyloid: data from the Women’s healthy ageing project (2018) (5)
- AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE (2019) (5)
- IN VIVO IMAGING OF BRAIN MUSCARINIC RECEPTORS WITH 18F-FLUROBENZYL DEXETIMIDE: FIRST IN HUMAN STUDIES (2019) (5)
- PET-only 18F-AV1451 tau quantification (2017) (5)
- 11C-PIB PET imaging in the differential diagnosis of dementia (2006) (5)
- Aβ amyloid, cognition and APOE genotype in the preclinical stages of Alzheimer's disease (2012) (5)
- Novel fluorine-18 labeled 2-arylquinoline derivatives for imaging tau-pathology in Alzheimer's disease (2012) (4)
- A Copper Radiopharmaceutical for Diagnostic Imaging of Alzheimer′s Disease: A Bis(thiosemicarbazonato)copper(II) Complex That Binds to Amyloid‐β Plaques. (2010) (4)
- The natural history of the dynamics of beta-amyloid deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease (2013) (4)
- MR-Less Surface-Based Amyloid Estimation by Subject-Specific Atlas Selection and Bayesian Fusion (2012) (4)
- Amyloid-beta: The seeds of darkness (2011) (4)
- D2 dopamine receptors in drug naive schizophrenics: update on 20 subjects (1989) (4)
- Quantitative approaches to amyloid imaging. (2011) (4)
- Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment (2022) (4)
- A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping (2017) (4)
- Generative atlases and atlas selection for C11-PIB PET-PET registration of elderly, mild cognitive impaired and Alzheimer disease patients (2008) (4)
- Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions (2014) (4)
- Untangling tau imaging (2016) (4)
- AT(N) predicts near-term development of Alzheimer's disease symptoms in unimpaired older adults (2022) (4)
- Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (European Journal of Nuclear Medicine and Molecular Imaging, (2017), 44, 3, (353-357), 10.1007/s00259-016-3589-9) (2017) (4)
- Plasma glial fi brillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer ’ s disease (2021) (4)
- Manifold drived MR-less PiB SUVR normalisation (2012) (4)
- Generating continuous and categorical measures from tau imaging studies with 18F-AV1451 and 18F-THK5351: The Tau MeTeR scale (2016) (4)
- Update on PET methods for D2 dopamine receptors in schizophrenia and bipolar disorder (1989) (4)
- Anti-Aβ antibody target engagement: a response to Siemers et al. (2014) (4)
- Investigating the synergistic relationship between sleep quality, physical activity, and levels of brain beta-amyloid (2015) (4)
- Microbleeds and clinical trajectories: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (2013) (4)
- Mesial temporal tau in amyloid-β-negative cognitively normal older persons (2022) (4)
- Rare genetically defined causes of dementia (2005) (4)
- The heritability of amyloid burden in older adults: the Older Australian Twins Study (2021) (3)
- In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy individuals from those with preclinical Alzheimer's disease (2013) (3)
- CORRELATION OF AMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER’S DISEASE (2018) (3)
- Neutrophil-lymphocyte ratio in Alzheimer's disease: Data from the Australian Imaging Biomarker and Lifestyle study of ageing (2013) (3)
- Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults (2022) (3)
- Future Directions in Molecular Imaging of Neurodegenerative Disorders. (2022) (3)
- 18F-Florbetaben-pet imaging in the differential diagnosis of dementia (2010) (3)
- Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and 18F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease (2021) (3)
- F-florbetaben A β imaging in mild cognitive impairment (2013) (3)
- Larger temporal volume in asymptomatic elderly with high versus low beta-amyloid deposition (2010) (3)
- Predictors of cognitive decline at 18 month follow up among 1112 participants in the Australian imaging, biomarkers and lifestyle flagship study of ageing (AIBL) (2011) (3)
- Divergent Network Patterns of Amyloid-β Deposition in Logopenic and Amnestic Alzheimer's Disease Presentations. (2016) (3)
- The dawn of robust individualised risk models for dementia (2019) (3)
- Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. (2020) (3)
- Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease (2022) (3)
- THE TAU METER SCALE FOR THE GENERATION OF CONTINUOUS AND CATEGORICAL MEASURES OF TAU DEPOSITS IN THE BRAIN: RESULTS FROM 18F-AV1451 AND 18F-THK5351 TAU IMAGING STUDIES (2016) (3)
- Can amyloid PET differentiate “pure” LBD from AD with or without LBD copathology? (2019) (3)
- Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease? (2018) (3)
- 11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous. (2021) (3)
- Effects of extracellular acetylcholine on muscarinic receptor binding assessed by [125I]dexetimide and a simple probe. (1998) (3)
- Aβ accumulation in non-demented individuals: A longitudinal F-18-flutemetamol study (2015) (3)
- Human biodistribution and internal dosimetry of 4-[ 18F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart (2020) (3)
- Variability in blood-based beta-amyloid assays: The need for consensus on preanalytical processing (2012) (3)
- In vivo tau imaging in Alzheimer's disease and other dementias (2012) (3)
- β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3 (2022) (3)
- Characterisation of [18F]-THK523, a novel in vivo tau imaging ligand (2010) (2)
- Beta-amyloid imaging and memory in a large cohort of elderly individuals (2008) (2)
- β-amyloid in biological samples: not all Aβ detection methods are created equal (2014) (2)
- OPL204 Amyloid imaging in Lewy Body Dementia with 11C-PIB-PET (2005) (2)
- THE ASSOCIATION BETWEEN AMYLOID BURDEN AND SUB-CLINICAL DEPRESSION IN HEALTHY OLDER ADULTS (2014) (2)
- Cognitive consequences of high beta-amyloid levels in people with mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease (2013) (2)
- Nicotinic receptor imaging with 2-[18F]F-A-85380 PET does not differentiate early Alzheimer's disease patients from healthy controls (2007) (2)
- Serotonin Transporter Binding In Vivo (2001) (2)
- 18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy (2022) (2)
- Supervised method to build an atlas database for multi-atlas segmentation-propagation (2010) (2)
- CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
- Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL) (2013) (2)
- Rates of conversion to MCI and Alzheimer's in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort over 36 months (2012) (2)
- 0 Effects of Attenuation on Tumor Detection in PET Oncology (2001) (2)
- Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease (2022) (2)
- Alzheimer’s disease biomarker roadmap 2020: Fluid biomarkers (2020) (2)
- Alzheimer’s disease biomarker roadmap 2020: Second‐generation tau PET tracers (2020) (2)
- 18F‐MK6240 longitudinal tau PET in ageing and Alzheimer’s disease (2021) (2)
- Automatic Detection of Cerebral Microbleed in SWI Using Radon Transform (2013) (2)
- Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET study (2022) (2)
- CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
- AMYLOID β-RELATED COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE IS MODERATED BY APOE AND BDNF POLYMORPHISMS (2014) (2)
- O3-06-07 C-11 PIB PET amyloid imaging in aging and dementia (2006) (2)
- MESIAL TEMPORAL TAU BURDEN IN OLDER ADULTS WITH SUBJECTIVE MEMORY COMPLAINTS RELATES TO POORER MEMORY FUNCTION (2016) (2)
- Combining PIB and FDG PET data to distinguish AD patients from normal controls: A multi-modal partial least square approach (2008) (2)
- Elevated PiB precedes dementia in autosomal dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (2)
- Alzheimer's disease detection using 11C-PiB with improved partial volume effect correction (2009) (2)
- Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: Predictive value of Aβ imaging with 18F-Florbetaben (2011) (2)
- The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults (2022) (2)
- Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer’s Disease (2022) (2)
- Atrophy , hypometabolism and clinical trajectories in amyloid negative probable AD patients (2018) (2)
- Cognition, hippocampal volume and fibrillar Aβ burden as predictors of cognitive decline: Three-year follow-up results from AIBL (2012) (2)
- Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition (2021) (2)
- D2 dopamine receptors increased in psychotic, but not non-psychotic affective disorder (1989) (2)
- Cross-sectional and Longitudinal Analysis of the Relationship Between A β Deposition , Cortical Thickness , andMemory in Cognitively Unimpaired Individuals and in Alzheimer Disease (2013) (2)
- Apparent fibre density: A novel MRI approach that identifies specific white matter tracts affected in Alzheimer's disease and MCI (2012) (2)
- DETECTION OF PRODROMAL ALZHEIMER'S DISEASE WITH 18F-FLORBETABEN Aβ IMAGING: A PROSPECTIVE OUTCOME STUDY (2014) (2)
- A surface based approach for cortical thickness comparison between PiB+ and PiB- healthy control subjects (2012) (2)
- TO TAU OR TO MAO-B? MOST OF THE [F-18]-THK5351 SIGNAL IS BLOCKED BY SELEGILINE (2018) (2)
- The biomarker roadmap for the validation for Alzheimer’s biomarkers: Methodological update for biomarkers of tauopathy (2020) (2)
- Proceedings of the International Society for Magnetic Resonance in Medicine. Salt Lake City, Utah, USA (2013) (2)
- Amyloid imaging (2011) (2)
- Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis (2016) (2)
- Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases (2022) (2)
- Amyloid imaging in Alzheimer's disease: Relationships to memory deficits, brain atrophy, and hypometabolism (2012) (2)
- O1-04-03 Amyloid burden in ageing subjects with and without cognitive decline (2007) (2)
- The interaction between physical activity and sleep on cognitive function and brain beta-amyloid in older adults (2022) (2)
- Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies (2022) (1)
- Mediterranean diet adherence is associated with less cerebral amyloid accumulation over time: Data from the australian imaging, biomarkers, and lifestyle study of ageing (2015) (1)
- New developments in molecular imaging of the pathology of neurodegeneration (2014) (1)
- COMPARISON OF 18F-FLORBETABEN QUANTIFICATION RESULTS USING MR-BASED AND MR-LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY (2017) (1)
- Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease (2020) (1)
- Correlating the frontal presentation of Alzheimer's disease with frontal metabolism as measured by FDG-PET (2012) (1)
- The effect of vascular risk factors on cognition in older adults: Data from the AIBL study (2012) (1)
- P2-317 In vitro characterization of PIB binding to α-synuclein (2006) (1)
- Multimodality Imaging Population Analysis using Manifold Learning (2011) (1)
- Dynamic of Beta-amyloid deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a PiB-PET longitudinal study (2011) (1)
- Diminished white matter integrity four decades after traumatic brain injury in Vietnam War veterans (2021) (1)
- Aβ accumulation correlates with cognitive decline: results from the longitudinal AIBL study (2011) (1)
- The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers (2009) (1)
- Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging (2020) (1)
- Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study (2011) (1)
- IC-P3-226: Prevalence of Aβ positive 11C-PiB PET studies in healthy elderly subjects parallels neuropathology findings (2008) (1)
- VISUAL ASSESSMENT OF β-AMYLOID PET SCAN IS IMPROVED BY CAPAIBL (2018) (1)
- PTSD AND RISK OF ALZHEIMER’S DISEASE IN AUSTRALIAN VIETNAM VETERANS: AMYLOID AND TAU PET FINDINGS FROM AIBL-VETS (2017) (1)
- Alzheimer’s disease biomarker roadmap 2020: [ 18 F]flortaucipir: Strategic roadmap for the translation of tau biomarkers in the clinic: An international task force (2020) (1)
- ADVANCED DIFFUSION MRI ENABLES IN VIVO INVESTIGATION OF MICROSTRUCTURAL HETEROGENEITY OF WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE (2018) (1)
- Imago Mundi, Imago AD, Imago ADNI (2014) (1)
- CEREBRAL BLOOD FLOW, OXYGEN AND GLUCOSE METABOLISM IN JEOPARDIZED CEREBRUM AFTER EXPERIMENTAL STROKE (1988) (1)
- REVISITING, REVISING AND REFINING THE NATURAL HISTORY OF AB DEPOSITION AND ITS EFFECTS ON NEURODEGENERATION AND COGNITIVE DECLINE IN SPORADIC ALZHEIMER’S DISEASE (2016) (1)
- Evaluation of the novel 18F‐labeled PET tracer SMBT‐1 for imaging astrogliosis in healthy elderly controls and A+/T+/(N+) Alzheimer's disease patients (2020) (1)
- Cognitive change and Aβ deposition in MCI subjects studied with serial 18F-florbetaben PET over 2 years (2012) (1)
- Novel CYP1B1-RMDN2 Alzheimers disease locus identified by genome-wide association analysis of cerebral tau deposition on PET (2023) (1)
- Longitudinal assessment of A beta accumulation in non-demented individuals: A F-18-flutemetamol study (2015) (1)
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum. (2022) (1)
- IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F-FLORBETABEN AND 18F-NAV4694 USING CAPAIBL (2017) (1)
- Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. (2021) (1)
- A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging (2018) (1)
- Relation between amyloid burden, brain atrophy and memory in Alzheimer's disease (2009) (1)
- Early detection of amyloid load using 18F-florbetaben PET (2021) (1)
- Comparisons of animal-human translated and human 18F-BAY94-9172 amyloid radiation dosimetry (2009) (1)
- Comparison of 11C-PiB and 18F-AZD4694 for A{beta} imaging in ageing and dementia (2012) (1)
- FIXEL-BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE (2017) (1)
- Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort. (2023) (1)
- Brain health correlates of mobility-related confidence (2022) (1)
- FDG-PET improves diagnosis in patients presenting with focal onset variants of Alzheimer's disease (2014) (1)
- From the CSIRO Preventative Health Flagship (1913) (1)
- In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy controls from preclinical Alzheimer's disease (2013) (1)
- IMPLEMENTING THE ATN CLASSIFICATION IN AIBL (2017) (1)
- A data-derived Aβ biomarker model computed using longitudinal PIB data from AIBL (2012) (1)
- In vivo quantification of striatal VMAT2 with [F-18] AV133 (2009) (1)
- THE INFLUENCE OF LOW-DENSITY LIPOPROTEINS ON NEOCORTICAL AMYLOID LOAD IN THE AUSTRALIAN IMAGING BIOMARKER AND LIFESTYLE STUDY (2017) (1)
- Interaction between 18F-THK5317, 18F-flutemetamol SUVR, and cortical thickness (2015) (1)
- Progressive white matter abnormalities in autosomal dominant Alzheimer's disease: Results of the DIAN study (2012) (1)
- IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F-FLORBETABEN AND 18F-NAV4694 USING CAPAIBL (2017) (1)
- EFFECTS OF MAPT OVER BRAIN GREY MATTER ATROPHY IN THE AIBL COHORT (2016) (1)
- Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology (2020) (1)
- O1-04-06 Correlation of memory dysfunction and amyloid burden in mild cognitive impairment (2007) (1)
- Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume (2022) (1)
- Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β (2022) (1)
- Plasma beta-amyloid levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden (2013) (1)
- Longitudinal analysis of cortical thickness in PiB+ and PiB- healthy elderly controls (2012) (1)
- The effects of APOE4 on the rate of atrophy and Aβ deposition in asymptomatic elderly (2011) (1)
- A longitudinal study of {beta}-amyloid deposition with 11C-PiB-PET (2008) (1)
- Aβ accumulation correlates with cognitive decline: results from the longitudinal AIBL study (2011) (1)
- Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease (2023) (1)
- THE CHALLENGES AHEAD FOR PET IMAGING OF PROGRESSIVE PROTEINOPATHIES (2016) (1)
- Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate Aβ in Down Syndrome and Sporadic Alzheimer’s Disease (2021) (1)
- Worster-Drought Syndrome (Familial British Dementia): A Case Report (2010) (1)
- Correlation between white matter hyperintensities in MRI-FLAIR and 11C-PiB PET retention. A new potential for early identification of disease (2009) (1)
- Comparing Amyloid PET Tracers and Interpretation Strategies: First Results from the CAPTAINs Study (2018) (1)
- AN EXPLORATORY MOLECULAR IMAGING STUDY TARGETING Aβ WITH A NOVEL 8-OH QUINOLINE IN ALZHEIMER’S DISEASE (THE PBT2-204 IMAGINE STUDY) (2016) (1)
- Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease (2022) (1)
- Comparison of biomarkers for the prediction of cognitive decline (2010) (1)
- Longitudinal analysis of cortical thickness in PiB+ and PiB- healthy elderly controls (2012) (1)
- Genome‐wide study of the human lipidome and links to Alzheimer’s disease risk (2020) (1)
- Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study (2022) (1)
- PET image harmonization using smoothing-CycleGAN (2022) (1)
- Using the Artificial Neural Network to discriminate between normal controls with different APOE e4 genotypes and probable AD cases in PIB-PET studies (2009) (1)
- Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults (2017) (1)
- DOES ENHANCED RECONSTRUCTION METHODOLOGY CHANGE THE QUANTIFICATION OF AMYLOID PET WITH FLUMETAMOL? (2014) (1)
- ADVANCED DIFFUSION MRI ENABLES IN VIVO INVESTIGATION OF MICROSTRUCTURAL HETEROGENEITY OF WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE (2018) (1)
- The cognitive and brain volumetric trajectories of healthy elderly controls with either Alzheimer’s pathology, neurodegeneration (SNAP), or both (2015) (1)
- Disentangling the interaction between amyloid and tau: where are we now? (2016) (1)
- 11C-PiB-postmortem Aβ plaque load correlation (2010) (1)
- Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies (2022) (1)
- Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease (2021) (1)
- COGNITIVE SUPER-AGING VERSUS TYPICAL AGING IN COMMUNITY-DWELLING OLDER ADULTS: LONGITUDINAL TRAJECTORIES IN GLOBAL CORTICAL THICKNESS OVER SIX YEARS (2017) (1)
- CenTauRz: A standardized quantification of tau PET scans (2022) (1)
- FDG-PET improves diagnosis in patients presenting with focal onset dementias � (2015) (1)
- Neuropsychological predictors of autobiographical memory impairment in mild cognitive impairment (MCI) (2013) (1)
- A{beta} burden correlates with memory impairment in non-demented subjects but plateaus in established Alzheimer's disease: A PIB-PET cross sectional study (2007) (1)
- AU‐ARROW (Australia) (2020) (1)
- Gender-specific aging reductions in [11C-carbonyl] WAY100635 binding: Not an effect of atrophy (2000) (1)
- P1-153: The relationship between olfactory identification and memory and Abeta burden in Alzheimer's disease, mild cognitive impairment and healthy aging: A PIB-PET study (2008) (1)
- Assessing Aβ & tau pathology in Vietnam war veterans with chronic Post-Traumatic Stress Disorder (2016) (1)
- GENETIC ANALYSIS OF THE STEROIDOGENESIS PATHWAY: ASSOCIATIONS WITH ALZHEIMER'S DISEASE RISK AND RELATED PHENOTYPES (2014) (1)
- Alzheimer’s disease biomarker roadmap 2020: Time for tau (2020) (1)
- HIGHER AB BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIPL COHORTS (2014) (1)
- 81 In vivo tau imaging with PET (2012) (1)
- CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES (2019) (1)
- CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID-β RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLE OF HEALTHY OLDER ADULTS (2017) (1)
- Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions (2020) (1)
- 18F‐PI‐2620 tau‐PET in corticobasal syndrome (ActiGliA cohort) (2020) (1)
- Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels (2022) (1)
- Galantamine improves cognitive performance without effecting nicotinic receptors in early Alzheimer's disease as measured by 2[18F]F-A-85380 PET (2007) (1)
- COMPARISON OF 18F-FLORBETABEN QUANTIFICATION RESULTS USING MR-BASED AND MR-LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY (2017) (1)
- Pattern of A{beta} deposition in familial Alzheimer's disease is irrespective of mutation type or cognitive status (2008) (1)
- Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease (2020) (1)
- Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) (2013) (1)
- GRAPHICAL NETWORK ANALYSES INFORMS PET Aβ-AMYLOID BIOMARKER DISCOVERY VIA QUANTIFICATION OF INDIVIDUAL PEPTIDE CONNECTIONS (2017) (1)
- Ten-year MRI changes and FBB-PET: Results from the Women's Healthy Aging Project (WHAP) (2013) (1)
- DETECTION OF PRODROMAL ALZHEIMER'S DISEASE WITH 18F-FLORBETABEN AB IMAGING: A PROSPECTIVE OUTCOME STUDY (2014) (1)
- Focal Ab-amyloid deposition precedes cerebral microbleeds and Superficial siderosis: a case report (2017) (1)
- Test-retest variability of [18F]BAY 94-9172 studies in Alzheimer's disease and normal ageing (2009) (1)
- Registration of MRI - PET Images, Procedure and Validation (1988) (1)
- Before and After Amphetamine (2002) (1)
- P2-092: Prevalence of Aβ positive 11C-PiB PET studies in healthy elderly subjects parallels neuropathology findings (2008) (0)
- Characterisation of Pittsburgh Compound-B (PIB) binding to white matter (2007) (0)
- Imaging and cognitive biomarkers as predictors of progression to Alzheimer'S Disease (2012) (0)
- [Introduction to positron emission tomography]. (1991) (0)
- IN VIVO ASSESSMENT OF MARKERS OF ALZHEIMER’S DISEASE PATHOLOGY IN VIETNAM WAR VETERANS WITH CHRONIC POST-TRAUMATIC STRESS DISORDER (2016) (0)
- AMYLOID-POSITIVE VERSUS -NEGATIVE AMCI: SIMILARITIES AND DIFFERENCES IN NEUROPSYCHOLOGY AND NEUROIMAGING PROFILES (2016) (0)
- A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
- Improved centiloid robustness using non‐negative matrix factorization (2020) (0)
- Decreases in cerebral blood flow are associated with Aβ status in preclinical Alzheimer’s disease (2015) (0)
- Towards a universal cortical tau sampling mask (2020) (0)
- P3-084: Cerebrospinal fluid Tau and Aβ measurement and amyloid PET imaging in neurodegenerative diseases (2008) (0)
- Author Correction: Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2022) (0)
- A Targeted Association Study of Blood-Brain Barrier Gene SNPs and Brain Atrophy. (2022) (0)
- Centiloid harmonisation across PET cameras without using paired scan (2022) (0)
- Towards a universal cortical tau sampling mask (2021) (0)
- Biomarkers to unlock the Alzheimer?s disease pre-symptomatic window: Results from the AIBL Study (2013) (0)
- 18F-AV-133 VMAT2 Imaging in the Differential Diagnosis of Dementia With Lewy Bodies from Alzheimer's Disease (2010) (0)
- WHITE MATTER HYPERINTENSITIES, AMYLOID-β, AND RISK OF COGNITIVE DECLINE IN HEALTHY OLDER PEOPLE (2019) (0)
- EVIDENCE OF AMYLOID ON FLORBETABEN-PET IS ASSOCIATED WITH REDUCED EPISODIC MEMORY 10 YEARS PRIOR: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
- Correlation between white matter hyperintensities in MRI-FLAIR and 11C-PiB PET retention: A new potential for early identification of disease (2009) (0)
- IC-P3-208: In vivo characterization of 18F-BAY94-9172: A novel β-amyloid PET ligand for the diagnosis of Alzheimer's disease (2008) (0)
- TAU, Aβ-AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS (2018) (0)
- Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
- No association between presence of carotid disease and 11C-PiB-PET in acute stroke patients (2011) (0)
- Visual and semiquantitative validation of early and late Aβ imaging approaches using 18F-NAV4694 (2013) (0)
- Using ApoE ε4 carriage as a benchmark for modelling clinically meaningful treatment effects in clinical trials of preclinical Alzheimer’s disease (2015) (0)
- DIAGNOSTIC AND PROGNOSTIC POWER OF FLUID AND NEUROIMAGING MARKERS OF PATHOLOGY AND NEURODEGENERATION: THE ALZHEIMER'S IMAGING, BIOMARKERS, AND LIFESTYLE (AIBL) STUDY OF AGEING EXPERIENCE (2017) (0)
- APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles (2023) (0)
- Radiation dosimetry of the amyloid imaging agent 18F-BAY94-9172 in humans (2008) (0)
- INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY (2018) (0)
- ALTERED PERIPHERAL MONOCYTE INNATE PHAGOCYTOSIS IN ALZHEIMER’S DISEASE (2016) (0)
- IC-P2-149: In vivo assessment of β-amyloid deposition: A longitudinal study (2008) (0)
- Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. (2022) (0)
- FAILURE TO SHOW A PRACTICE EFFECT ON MEMORY TESTING IS A COGNITIVE MARKER OF MCI DUE TO ALZHEIMER'S DISEASE (2016) (0)
- AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE TO MALES: FINDINGS FROM TWO INDEPENDENT COHORTS (2018) (0)
- Alzheimer’s disease biomarker roadmap 2020: [18F]flortaucipir (2020) (0)
- CLINICAL MEANINGFULNESS OF SHORT-TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE-5 (PACC-5) IN NORMAL OLDER ADULTS WITH ELEVATED β-AMYLOID (2019) (0)
- GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS (2017) (0)
- IC-P1-046: Examining the regional specificity between Aβ burden and cognition (2008) (0)
- Subcortical tau‐accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R‐tauopathies (2022) (0)
- Molecular Imaging of Neurodegeneration: The Way to New Horizons. (2022) (0)
- Total plasma Aβ42/40 ratio is an early biomarker of Alzheimer’s disease progression (2015) (0)
- PRECLINICAL ALZHEIMER’S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY (2018) (0)
- P-032 Differentiation between Alzheimer’s disease patients and healthy controls is not possible with 2-[18F]F-A-85380 pet imaging of nicotinic receptors (2007) (0)
- BRAIN BETA-AMYLOID, VASCULAR FACTORS, AND COGNITION: 54-MONTH FOLLOWUP RESULTS FROM THE AIPL STUDY (2014) (0)
- Clinical utility of the cogstate brief battery in Alzheimer's disease–related memory impairment (2013) (0)
- VISUAL ASSESSMENT OF β-AMYLOID PET SCAN IS IMPROVED BY CAPAIBL (2018) (0)
- IL-10 AND IL-12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF Aβ-AMYLOID LOAD IN A BROADER BLOOD-BASED BIOMARKER PANEL (2017) (0)
- Test-retest variability studies in Alzheimer's disease and normal ageing of the new amyloid imaging agent [18F]BAY 94-9172 (2009) (0)
- Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer’s disease: The AIBL study (2020) (0)
- CSF P-TAU IS CORRELATED WITH TAU PET, WHILE Aβ PET CORRELATES WITH Aβ1-42 AND THE T-TAU/Aβ1-42 RATIO (2017) (0)
- PLASMA BIOMARKERS OF NEOCORTICAL AMYLOID BURDEN: AN IN-DEPTH PLASMA PROFILE USING LC-MS (2016) (0)
- IC-P-022 C-11 PIB PET amyloid imaging in ageing and dementia (2006) (0)
- Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification. (2022) (0)
- Cerebral microbleeds, brain beta-amyloid and clinical trajectories: results from the AIBL study of ageing (2013) (0)
- Prediction of Aß and clinical outcome in patients with MCI with neuropsychological tests (2012) (0)
- Cognitive change and beta-amyloid deposition in MCI subjects studied with serial 18F-Florbetaben PET over 2 years (2012) (0)
- Cross‐sectional and longitudinal comparison of 18F‐MK6240 and 18F‐Flortaucipir in populations matched for centiloid, age and MMSE (2022) (0)
- Novel 18F-labeled quinoline derivatives for in vivo detection of tau pathology in Alzheimer's disease (2012) (0)
- INCREASED CEREBRAL BLOOD FLOW WITH INCREASED AMYLOID BURDEN IN PRECLINICAL AD (2018) (0)
- KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden (2018) (0)
- BRAIN BETA-AMYLOID, VASCULAR FACTORS, AND COGNITION: 54-MONTH FOLLOWUP RESULTS FROM THE AIPL STUDY (2014) (0)
- UTILITY OF THE COGNIGRAM BRIEF BATTERY IN ASSESSING COGNITIVE CHANGES ASSOCIATED WITH AB AND APOE GENOTYPE IN PRECLINICAL ALZHEIMER'S DISEASE (2014) (0)
- The management impact of [18F]AV-133 VMAT2 PET in atypical Parkinson’s disease (2014) (0)
- P2.097 A reactive nitrogen species scavenger is neuroprotective in multiple Parkinson's disease animal models (2009) (0)
- QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN A b + ELDERLY CONTROLS AND ALZHEIMER’S DISEASE PATIENTS (2017) (0)
- P-066 Characterization of PIB binding to white matter (2007) (0)
- Detectable levels of white matter PHF-tau in Alzheimer's disease (2013) (0)
- NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
- The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions (2022) (0)
- 45. Gender differences in aging effect on the 5-HTlA receptor with [11C-carbonyl]way100635 PET (2000) (0)
- REGIONAL ASSOCIATION BETWEEN CORTICAL VOLUMES AND IMAGING TAU PATHOLOGY USING 18F-AV1451 AND 18F-THK5351 (2016) (0)
- Correlation between Amyloid Burden and Memory Impairment: A C-PIB PET Cross Sectional Study (2008) (0)
- IC-P-012 C-11 PIB and F-18 FDG in the diagnosis of Alzheimer’s disease (2006) (0)
- A retinal hyperspectral imaging biomarker for Alzheimer’s disease: Preliminary study of the influence of eye diseases on imaging scores (2020) (0)
- MR-less cortical surface-projection of PET images from 11C- and 18F-labeled radiotracers (2013) (0)
- Genetic risk for attention‐deficit/hyperactivity disorder is associated with amyloid‐dependent cognitive decline in older adults (2022) (0)
- LONGITUDINAL RATES OF ATROPHY IN FAMILIAL ALZHEIMER'S DISEASE (2014) (0)
- EFFECTS OF MAPT OVER BRAIN GREY MATTER ATROPHY IN THE AIBL COHORT (2016) (0)
- PLASMA BIOMARKER WITH HIGH ACCURACY IN PREDICTING BRAIN AMYLOID-β BURDEN: INITIAL RESULTS ACROSS TWO INDEPENDENT LARGE COHORTS—NCGG (JAPAN) AND AIBL (AUSTRALIA) (2018) (0)
- Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. (2023) (0)
- The Australian Biomarker, Imaging and Lifestyle Study: Phase I amyloid imaging results (2009) (0)
- Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals (2022) (0)
- Examining the structural correlates of amyloid‐beta in people with DLB (2021) (0)
- The trinity of tau, trauma, and time (2019) (0)
- A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort (2017) (0)
- Progress of the australian imaging, biomarkers, and lifestyle (AIBL) cohort with 72 months of assessment: Attrition, disease progression, and mortality (2015) (0)
- O2-13-04 WHITE MATTER HYPERINTENSITIES AND CSF BIOMARKERS IN RELATION TO CLINICAL SYMPTOM ONSET IN PRECLINICAL ALZHEIMER’S DISEASE (2018) (0)
- Identification of genetic markers linked to accelerated brain volume changes in Aβ‐positive population (2020) (0)
- Head‐to‐Head comparison between Philips Gemini TF64 and Siemens Biograph Vision 600 for brain amyloid Centiloid quantitation (2022) (0)
- Amyloid angiopathy may contribute to white‐matter hyperintensities in Alzheimer’s disease (2020) (0)
- Evaluation of the novel F-18-labeled PET tracer SMBT-1 for imaging astrogliosis in Alzheimer's disease (2020) (0)
- 18F-AV-133 VMAT2 imaging in the differential diagnosis of dementia with Lewy Bodies from Alzheimer's disease (2010) (0)
- VERBAL LEARNING AND BETA-AMYLOID: REPEATED ADMINISTRATION OF THE INTERNATIONAL SHOPPING LIST TEST (2018) (0)
- PET IMAGING OF BRAIN MUSCARINIC M1 RECEPTORS WITH F-18-FLUROBENZYL DEXETIMIDE: FIRST IN HUMAN STUDIES (2019) (0)
- Higher coffee consumption is associated with slower cognitive decline and Aβ‐amyloid accumulation over 126 months: Data from the AIBL study (2021) (0)
- Self-reported confusion is related to global and regional β-amyloid: data from the Women’s healthy ageing project (2017) (0)
- NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
- AMYLOID-POSITIVE VERSUS NEGATIVE AMCI: SIMILARITIES AND DIFFERENCES IN NEUROPSYCHOLOGY AND NEUROIMAGING PROFILES (2016) (0)
- BDNF, Aβ, and cortical atrophy in preclinical Alzheimer's disease (2015) (0)
- Aβ-related memory decline in preclinical Alzheimer's disease is delayed in ApoE-ɛ4 non-carriers (2015) (0)
- O2-06-05 CORRELATION OFAMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER’S DISEASE (2018) (0)
- REFINING THE NATURAL HISTORY OF GLOBAL AND REGIONAL Aβ-AMYLOID DEPOSITION IN SPORADIC ALZHEIMER’S DISEASE (2017) (0)
- AGE INCREASES RATE OF AB- AND E4-RELATED MEMORY DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
- MIDLIFE VASCULAR RISK, APOLIPOPROTEIN E-E4, AND AMYLOID STATUS 20 YEARS LATER: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
- Amyloid imaging: what can it tell us? (2016) (0)
- Plasma glial fibrillary acidic protein is associated with reactive astrogliosis assessed via 18F‐SMBT‐1 PET (2022) (0)
- Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
- O1-04-02 Initial results from human studies of a novel F-18 PET ligand for brain beta-amyloid imaging (2007) (0)
- TAU, Aß AND COGNITION IN HEALTHY ELDERLY: PRELIMINARY DATA FROM THE AIBL COHORT (2016) (0)
- PiB as antecedent biomarker of Alzheimer's disease (2009) (0)
- Relationship between longitudinal changes in amyloid deposition and incident dementia in non‐demented individuals age 80+ (2022) (0)
- IC-P-084 Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer’s disease: A human in vivo study using [18F]F-A-85380 PET (2006) (0)
- The Lancet Neurology Amyloid and FDG-PET in the diagnostic work-up of Alzheimer’s disease and other dementias (2020) (0)
- A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease (2016) (0)
- Correlation of PiB-PET to post-mortem A{beta} plaque load (2010) (0)
- Combining white matter density and atrophy information to improve the characterization of axonal loss in Alzheimer's disease (2013) (0)
- PARTIAL VOLUME CORRECTION USING EITHER PMOD ® OR CAPAIBL ® DOES LITTLE TO IMPROVE 18F-AV1451 PET QUANTIFICATION (2018) (0)
- P-092 Nicotinic receptors are not responsible for improved cognitive performance by galantamine in early Alzheimer’s disease: A 2-[18F]f-a-85380 PET study (2007) (0)
- EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND Aβ-ASSOCIATED MEMORY DECLINE OVER 8 YEARS (2018) (0)
- Cognitive & Behavioral Assessment Sensitivity of composite scores to amyloid burden in preclinical Alzheimer'sdisease:IntroducingtheZ-scoresofAttention,Verbalfluency, and Episodic memory for Nondemented older adults composite score (2016) (0)
- PLASMA CORTISOL, AMYLOID-B, AND COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
- P1-384 Association of AD neuropathological hallmarks with biological metals (2006) (0)
- In an amnestic MCI population, those with high PIB binding perform more poorly on memory tests than those with low binding (2010) (0)
- The Australian Imaging, Biomarkers and Lifestyle-Rate of Change sub-study (AIBL-ROCS): Rationale, design, acceptability and pilot data for the first three months of assessment (2012) (0)
- Effect of Aβ burden and apolipoprotein E-ε4 on cognitive decline at 18 months in healthy older adults (2012) (0)
- Beta-amyloid imaging with 18F-BAY94-9172 (AV1/ZK) PET in the differential diagnosis of Alzheimer's disease from fronto-temporal lobar degeneration (2008) (0)
- Objectively measured physical activity and cognition in cognitively normal older adults: A longitudinal analysis of the Australian Imaging Biomarkers and Lifestyle (AIBL) study (2022) (0)
- Longitudinal modeling of joint PIB/MRI changes in Alzheimer's disease (2012) (0)
- AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS (2019) (0)
- 35. Cocaine-related cues elicit craving and activate cortical circuits relevant to episodic memory (1996) (0)
- Identification of neurodevelopmental gene variants implicated in age‐related brain morphological changes and cortical atrophy (2021) (0)
- Sigmoidal kinetics of BETA-AMYLOID deposition: Twenty-year interval between normality and fully developed Alzheimer's disease (2012) (0)
- Subcortical tau‐accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R‐tauopathies (2022) (0)
- Semi‐quantitative [11C]PiB and [15O]H2O PET measures of cerebrospinal fluid dynamics discriminate amyloid load but not cognitive status (2021) (0)
- Suboptimal sleep efficiency and duration predicts rate of accumulation of Aβ‐ Amyloid in cognitively normal older adults (2022) (0)
- PRECLINICAL EFFECTS OF Aβ DEPOSITION ON EPISODIC MEMORY AND DISEASE PROGRESSION (2014) (0)
- Improved Imaging-Based Diagnosis of PSP by [F-18]PI-2620 Tau PET (2020) (0)
- Cerebral microbleeds in dementia with Lewy bodies. (2022) (0)
- GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS (2017) (0)
- THK523 selectively binds to neurofibrillary tangles and neuropils in people with Alzheimer's disease (2013) (0)
- 101. Brain Amyloid Imaging with 11C-PIB PET (2009) (0)
- DIFFERENTIAL RISK FACTORS FOR PROGRESSION TO MCI/DEMENTIA BY AMYLOID-BETA STATUS (2018) (0)
- Longitudinal evaluation of basal forebrain atrophy and its association to beta-amyloid burden and hippocampal volume in Alzheimer's disease (2013) (0)
- O4-02-05 Total exchangeable Cu2+ protein binding sites are elevated in Alzheimer’s disease (2006) (0)
- When is Progressive Aphasia Due to Alzheimer's Disease? A PIB-PET Study (2010) (0)
- One year tau progression measured with F‐18 MK6240 PET (2020) (0)
- PARTIAL VOLUME CORRECTION USING EITHER PMOD (cid:1) OR CAPAIBL (cid:1) DOES (2018) (0)
- RECEIVER OPERATING CHARACTERISTICS (ROC) OF FLOW AND AMYLOID LOAD INDICES FROM BRAIN MAPS OF [11C]PIB RETENTION IN ALZHEIMER'S DISEASE (2014) (0)
- C-11 PIB PET imaging in atypical presentation of Alzheimer's disease (2006) (0)
- 313: Imaging brain amyloid in ageing and dementia with C-11 PIB PET (2007) (0)
- Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
- ASSESSING THE ACCURACY OF A CT-BASED APPROACH TO THE PARTIAL VOLUME CORRECTION OF FLUTEMETAMOL-PET IMAGES (2014) (0)
- Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia (2016) (0)
- TAU IMAGING WITH 18F-MK6240 IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAS (2019) (0)
- IC‐P‐172: Withdrawn (2015) (0)
- How lifestyle shapes the brain: Associations between physical activity, sleep, beta‐amyloid and cognitive function in older adults (2021) (0)
- Between SNAP and a hard Aβ rock: Characterizing the fate of preclinical Alzheimer's disease (2015) (0)
- Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study (2015) (0)
- O1-02-07: In vivo characterization of 18F-BAY94-9172: A novel β-amyloid PET ligand for the diagnosis of Alzheimer's disease (2008) (0)
- RECENT FINDINGS OF NOVEL BLOOD COMPONENTS’ AMYLOID-BETA MEASURES (2019) (0)
- Healthy subjects with abnormal levels of amyloid‐B and tau have lower cortical volumes in the mesial temporal region (2020) (0)
- Modulation of beta-amyloid-related cognitive decline by brain-derived neurotrophic factor Val66Met polymorphism in preclinical Alzheimer's disease (2013) (0)
- Longitudinal modeling of joint PiB/MRI changes in Alzheimer's disease (2012) (0)
- Cerebral microhaemorrhage and brain A{beta} in healthy ageing and Alzheimer's disease (2011) (0)
- Empirically derived composite cognitive test scores to predict preclinical and clinical stages of Alzheimer’s disease (2021) (0)
- LONGITUDINAL ASSESSMENT OF Aβ ACCUMULATION WITH FLUTEMETAMOL (2017) (0)
- D 2 dopamine receptors in pituitary tumors (1987) (0)
- Progressive white matter abnormalities in autosomal-dominant Alzheimer's disease: Results of the DIAN study (2012) (0)
- Differential diagnosis of dementia with Lewy bodies from Alzheimer's disease using [18F]-AV-133, a novel PET tracer for VMAT2 (2010) (0)
- BDNF, Aβ, and cortical atrophy in preclinical Alzheimer's disease (2015) (0)
- Postmortem neocortical 3 H‐PiB binding and levels of unmodified and pyroglutamate Aβ in Down syndrome and sporadic Alzheimer’s disease (2022) (0)
- PiB PET Classification: A model to determine those who are at risk of developing AD (2009) (0)
- EVIDENCE OF AMYLOID ON FLORBETABEN-PET IS ASSOCIATED WITH REDUCED EPISODIC MEMORY 10 YEARS PRIOR: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
- The consequences of Aβ deposition in aging and Alzheimer's disease: Results from 366 elderly subjects (2011) (0)
- REGIONAL ASSOCIATION BETWEEN CORTICAL VOLUMES AND IMAGING TAU PATHOLOGY USING 18F-AV1451 AND 18F-THK5351 (2016) (0)
- Implementation of the centiloid transformation for F-18 nav4694: Comparison with PiB (2015) (0)
- Combining two large clinical cohorts (AIBL and ADNI) to identify multiple lipid metabolic pathways in prevalent and incident Alzheimer's disease. (2020) (0)
- Amyloid imaging in Alzheimer’s disease and dementia with lewy bodies with 11C-PIB-PET (2005) (0)
- THE LEWY STUDY: AN AUSTRALIAN LONGITUDINAL COHORT STUDY OF DEMENTIA WITH LEWY BODIES (2019) (0)
- Effects of partial volume correction on the analysis of 11C-PiB PET in assessing Alzheimer's disease (2010) (0)
- ANTIHYPERTENSIVE TREATMENT AND LONGITUDINAL Aβ MEASURES: RESULTS FROM THE AIBL STUDY OF AGEING (2016) (0)
- P2-291 C-11 PIB and F-18 FDG in the diagnosis of Alzheimer’s disease (2006) (0)
- BETA-AMYLOID SPECIFIC GENOMIC NETWORKS DEFINE CIS AND TRANS RELATIONSHIPS IN PARTICIPANTS WITH ALZHEIMER’S DISEASE (2018) (0)
- Characterizing patterns of atrophy between cognitively unimpaired healthy elderly controls with either Alzheimer's disease or suspected non-alzheimer's disease pathophysiology (2015) (0)
- Subjective memory complainers in the AIBL cohort: Hypervigilance amongst the worried well, or individuals at increased risk of Alzheimer's disease? (2010) (0)
- P3-171: Redefining “normal” cognitive performance in ageing using Aβ neuroimaging (2008) (0)
- Midlife vascular risk and late-life amyloid burden: Data from the Women's Healthy Ageing Project (WHAP) (2013) (0)
- DIFFERENCE IN THE RATE OF COGNITIVE CHANGE BETWEEN INDIVIDUALS WITH AND WITHOUT VASCULAR RISK FACTORS: A LONGITUDINAL STUDY (2016) (0)
- Apparent fibre density: A novel MRI approach that identifies specific white matter tracts affected in Alzheimer's disease and MCI (2012) (0)
- AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS (2019) (0)
- Subjective cognitive decline and Aβ status are associated with longitudinal episodic memory decline in cognitively normal older adults (2015) (0)
- β-AMYLOID AND TAU IMAGING IN OBSTRUCTIVE SLEEP APNOEA: AUSTRALIAN IMAGING BIOMARKERS AND LIFESTYLE-VETERANS STUDY (AIBL-VETS) (2017) (0)
- VASCULAR RISK MEASURES AND LONGITUDINAL Aβ ACCUMULATION: RESULTS FROM THE AIBL STUDY OF AGEING (2017) (0)
- Aβ RELATED MEMORY DECLINE AND HIPPOCAMPAL VOLUME LOSS IN MILD COGNITIVE IMPAIRMENT (2016) (0)
- A management impact study of VMAT2 PET with [18F]AV-133 in patients with uncertain parkinsonian features: Preliminary findings (2013) (0)
- The effect of vascular risk factors on the rate of cognitive change in older adults: Data from the Australian Imaging Biomarkers and Lifestyle (AIBL) flagship study (2013) (0)
- Mesial temporal tau in amyloid-β-negative cognitively normal older persons (2022) (0)
- P1-306: In vivo assessment of β-amyloid deposition: A longitudinal study (2008) (0)
- SPON1 Is Associated with Amyloid-β and APOE ε4-Related Cognitive Decline in Cognitively Normal Adults (2019) (0)
- Automatic 11C PiB SUVR quantification (2013) (0)
- FIXEL-BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE (2017) (0)
- S.26.03 Potential role of amyloid imaging in mild cognitive impairment in Parkinson's disease (2014) (0)
- Associations between gonadotropins, testosterone, plasma Aβ and PiB retention in men with subjective memory complaints or mild cognitive impairment (2010) (0)
- Emission Imaging in Dementia (2012) (0)
- Preclinical effects of A{beta} deposition on episodic memory and disease progression (2014) (0)
- Level of physical activity is associated with hippocampal volume in a subgroup of the AIBL cohort (2012) (0)
- An update on an AIBL blood-based biomarker panel for the prediction of Aβ burden (2012) (0)
- Characterizing patterns of atrophy between cognitively unimpaired healthy elderly controls with either Alzheimer's disease or suspected non-Alzheimer's disease pathophysiology (2015) (0)
- 18F-AV1451 TAU QUANTIFICATION WITHOUT MRI (2017) (0)
- P1-238: The Australian biomarker, imaging and lifestyle study: Preliminary PiB results (2008) (0)
- SENSITIVITY OF AN ALZHEIMER’S DISEASE COOPERATIVE STUDY: PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC) BASED ON COMPUTERIZED TESTS TO AMYLOID LOAD IN PRECLINICAL AD (2017) (0)
- A two-year longitudinal assessment of A{beta} deposition in MCI with 18F-Florbetaben (2012) (0)
- Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease (2023) (0)
- Recent advances in tau imaging (2014) (0)
- CEREBROVASCULAR DISEASE, ALZHEIMER’S DISEASE BIOMARKERS AND LONGITUDINAL COGNITIVE DECLINE (2016) (0)
- Elevated PiB precedes dementia in autosomal-dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (0)
- P2-009: Characterisation of [18]-BF227 binding to α-synuclein (2008) (0)
- EXOSOMAL MIRNA AS BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE (2014) (0)
- IC-03-03: The Australian Biomarker, Imaging and Lifestyle Study: Preliminary PIB results (2008) (0)
- PIB-PET CENTILOID QUANTIFICATION USING CAPAIBL (2016) (0)
- Cortical surface projection of PET images from 11C- and 18F-labeled radiotracers without magnetic resonance imaging (2013) (0)
- P3-462 CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID-b RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLEOF HEALTHY OLDER ADULTS (2017) (0)
- Blood Borne Aβ Dimer Correlates With Clinical Markers of Alzheimer's Disease (2009) (0)
- The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers (2009) (0)
- Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. (2023) (0)
- In vivo detection of tau protein deposits in Alzheimer's disease using 18F-labeled 2-phenylquinoline derivatives (2013) (0)
- Relation between rates of Aβ deposition, APOE genotype and cognition: Results from a 3- to 5-year longitudinal study (2012) (0)
- Amyloid-β and its relevance to the detection of Alzheimer's disease in blood plasma: Findings from the first phase of the Australian Imaging, Biomarker and Lifestyle (AIBL) flagship study of ageing (2009) (0)
- Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease (2022) (0)
- Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease (2020) (0)
- In vitro characterization of [F-18]-florbetaben, an A beta imaging radiotracer (2012) (0)
- PIB PET CENTILOID QUANTIFICATION USING CAPAIBL (2016) (0)
- Web-based automated PET and MR quantification (2015) (0)
- AUTOMATED REPORTING OF AMYLOID PET QUANTIFICATION ON BRAIN SURFACE THROUGH A WEB INTERFACE (2014) (0)
- MIDLIFE VASCULAR RISK, APOLIPOPROTEIN E-E4, AND AMYLOID STATUS 20 YEARS LATER: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
- Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans (2021) (0)
- Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies (2014) (0)
- CLINICAL MEANINGFULNESS OF SHORT-TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE-5 (PACC-5) IN NORMAL OLDER ADULTS WITH ELEVATED β-AMYLOID (2019) (0)
- A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY (2017) (0)
- Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimer’s disease (2021) (0)
- THE IMPACT OF APOE ε4 CARRIAGE ON Aβ-AMYLOID DEPOSITION IN AIBL (2017) (0)
- Identification of Pre-Clinical Alzheimer's Disease in a Population of Elderly Cognitively Normal Participants. (2019) (0)
- Combining white matter density and atrophy information to improve the characterization of axonal loss in Alzheimer's disease (2013) (0)
- Discordant low amyloid‐β PET and high neocortical tau PET retention (2021) (0)
- The amyloid-β pathway in Alzheimer's disease: a plain language summary. (2023) (0)
- Investigating a new neocortical mask for Centiloid quantification (2022) (0)
- A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
- TAU IMAGING IN ALZHEIMER’S DISEASE WITH [F-18]-MK6240, A SECOND GENERATION SELECTIVE TAU TRACER (2018) (0)
- COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβ-AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD (2018) (0)
- Differential Diagnosis of Dementia with FDG-PET and Voxel-Based Statistical Analysis: Impact of Alternative Normal Databases (2010) (0)
- 18F-AV1451 TAU QUANTIFICATION WITHOUT MRI (2017) (0)
- Gender differences in the relationship between Aβ burden and memory (2010) (0)
- O 104-06 CORRELATION OF MEMORY DYSFUNCTION AND AMYLOID BURDEN IN MILD COGNITIVE IMPAIRMENT (2007) (0)
- TAU, Aβ-AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS (2018) (0)
- AMNESTIC MILD COGNITIVE IMPAIRMENT ADULTS IN EVENT- RELATED POTENTIALS DURING MEMORY ENCODING IN AVISUOSPATIAL WORKING MEMORY TASK (2017) (0)
- COMPARISON OF EARLY DYNAMIC AMYLOID AND TAU-PET SCANS TO 18F-FDG-PET IMAGE (2016) (0)
- The consequences of Aβ deposition in aging and Alzheimer's disease: results from 366 elderly subjects (2011) (0)
- Tau imaging with 18F-MK6240 in Alzheimer’s disease and Traumatic Brain Injury (2019) (0)
- EFFECTS OF AB AND BDNF VAL66MET ON EPISODIC MEMORY, HIPPOCAMPAL VOLUME AND SERUM BDNF IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
- Comparison of PiB and FDG in the differential diagnosis of Alzheimer's disease (2008) (0)
- Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
- Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimerâ€TMs disease (2019) (0)
- Basal forebrain atrophy and tau pathology are correlated in prodromal AD (2020) (0)
- Molecular imaging in dementia: journey to the end of the night (2009) (0)
- TAU, Aβ-AMYLOID, AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN VIETNAM WAR VETERANS (2017) (0)
- The Neuroinflammatory Response in Plaqes and Amyloid Angiopathy in Alzheimer's Disease: Therapeutical Implications (2007) (0)
- AUTOMATED REPORTING OF AMYLOID PET QUANTIFICATION ON BRAIN SURFACE THROUGH A WEB INTERFACE (2014) (0)
- PARTIAL VOLUME CORRECTION USING EITHER PMOD® OR CAPAIBL® DOES LITTLE TO IMPROVE 18F-AV1451 PET QUANTIFICATION (2018) (0)
- GENETIC VARIATION WITHIN GENES OF THE SPHINGOLIPID METABOLISM PATHWAY AND THEIR ASSOCIATION WITH ALZHEIMER'S DISEASE RISK AND RELATED PHENOTYPES (2014) (0)
- APOE GENOTYPE-DEPENDENT EFFECTS OF DIET AND PHYSICAL ACTIVITY ON COGNITION AND ALZHEIMER'S-RELATED PATHOLOGY: DATA FROM THE AIPL STUDY OF AGEING (2014) (0)
- MK-6240-PET NEUROFIBRILLARY TANGLE PATTERN SUBTYPES ARE ASSOCIATED WITH DISTINCT MEMORY AND COGNITIVE PERFORMANCE (2019) (0)
- P2-371 Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer’s disease: A human in vivo study using [18F]F-A-85380 PET (2006) (0)
- THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS (2019) (0)
- ASSESSING GLOBAL AND REGIONAL Aβ-AMYLOID DEPOSITION IN THE BRAIN WITH MULTIPLE Aβ-TRACERS USING THE CENTILOID SCALE (2019) (0)
- Techniques for assessing Alzheimer's disease progression (2015) (0)
- PiB PET Classification: A model to determine those who are at risk of developing Alzheimer's disease (2009) (0)
- Implementation and validation of a method for automated quantification of [18F]flutemetamol imaging data (2012) (0)
- Exploring CSF biomarkers that add value to CSF AB42, t-Tau and p-Tau for correlation with β-amyloid PET status (2020) (0)
- Quantitative thresholds for 18F‐florbetaben PET for the detection of low amyloid load (2020) (0)
- Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
- Greater rate of atrophy in elderly with high versus low Aβ deposition (2011) (0)
- Interaction between 18F-THK5317, 18F-flutemetamol SUVR and cortical thickness (2015) (0)
- HIGHER Aβ BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIPL COHORTS (2014) (0)
- Identification of concordant plasma lipid signatures in Alzheimer’s disease: Validation between two independent studies of Alzheimer’s disease (2020) (0)
- [11C]WIN-35,428 PET Imaging Reveals Decreased Dopamine Transporter Density in Abstinent Methamphetamine Users (1998) (0)
- PET imaging of amyloid burden and cognitive assessment for the reliable discrimination between healthy aging, subjective memory impairment and mild cognitive impairment (2012) (0)
- Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
- Using imputation to harmonize longitudinal measures of cognition across two large cohorts: AIBL and ADNI (2020) (0)
- Comparing the longitudinal progression of CSF biomarkers with PET Amyloid biomarkers for Alzheimer’s disease (2022) (0)
- 316 - Lewy Body Study: An Australian longitudinal biomarker study of dementia with Lewy bodies (2020) (0)
- Preclinical and clinical imaging techniques as pathophysiological biomarkers — A preface to the special issue “Brain Imaging” (2022) (0)
- Investigating the impact of scatter correction on Centiloid (2021) (0)
- The association between mesial temporal tau with age, cognition and neocortical tau in Aβ cognitively unimpaired individuals using MK‐6240 (2020) (0)
- Unpacking cognitive composites: A longitudinal analysis (2021) (0)
- PARTICIPANTS WITH A POSITIVE AMYLOID SCAN IN THE WOMEN’S HEALTHY AGEING PROJECT HAD SIGNIFICANTLY WORSE EPISODIC MEMORY THAN THOSE WITH A NEGATIVE SCAN (2014) (0)
- Cognitive assessments as estimators of neocortical beta-amyloid burden in the AIBL cohort (2012) (0)
- MK-6240-PET NEUROFIBRILLARY TANGLE PATTERN SUBTYPES ARE ASSOCIATED WITH DISTINCT MEMORY AND COGNITIVE PERFORMANCE (2019) (0)
- Plasma p217+tau concordance with 18F‐NAV4694 beta‐amyloid and 18F‐MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort (2021) (0)
- P2-021: Profiling beta-amyloid in the Alzheimer's disease brain (2012) (0)
- P2-271 OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETACHANGEWITH 18F-FLORBETABEN PET (2019) (0)
- 18F-florbetaben Aβ imaging in mild cognitive impairment (2013) (0)
- Centiloid harmonisation strategies across longitudinal studies: Evaluation on AIBL, ADNI and OASIS3 (2021) (0)
- P2-054: Pattern of Aβ deposition in familial Alzheimer's disease is not related to mutation type or cognitive status (2008) (0)
- SELF-REPORTED PHYSICAL ACTIVITY IS ASSOCIATED WITH TAU BURDEN AS MEASURED BY PET (2017) (0)
- Automatic 11C PiB SUVR quantification (2013) (0)
- The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis. (2022) (0)
- Analysis of Peripheral Blood Biomarkers: Towards the Early Diagnosis Alzheimer's Disease (2010) (0)
- Altered levels of plasma kallikrein‐7 in prodromal Alzheimer’s disease (2022) (0)
- Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification (2022) (0)
- EANM Springer Prizes awarded at EANM’15 Hamburg (2015) (0)
- PAIRED ASSOCIATE LEARNING DEFICITS ASSOCIATED WITH ELEVATED BETA-AMYLOID IN COGNITIVELY NORMAL OLDER ADULTS (2018) (0)
- Divergent complex network patterns of amyloid-b deposition between language and typical alzheimer's presentations (2015) (0)
- COMORBIDITY OF CEREBROVASCULAR DISEASE AND AMYLOID-β AND ITS INFLUENCE ON RATES OF COGNITIVE DECLINE AND NEURODEGENERATION (2018) (0)
- The effects of mesial temporal tau in Ab‐negative cognitively normal older adults (2020) (0)
- Baseline and follow-up neuroimaging results from the Australian imaging, biomarker, and lifestyle flagship study of aging (AIBL) (2010) (0)
- Alzheimer’s disease specific MRI brain regions are differentially associated with accelerated decline as defined using sigmoidal cognitive turning point methodology in amyloid‐positive AIBL participants (2022) (0)
- Potential use of cogstate battery to monitor adverse events in individuals taking part in clinical trials of anti-amyloid drugs (2015) (0)
- Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden (2023) (0)
- Incidence and associations of lobar microbleeds: Results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) (2012) (0)
- Episodic memory decline is associated with cortical amyloid accumulation in healthy community-dwelling, non demented older adults (2011) (0)
- P1-277: Examining the regional specificity between Aβ burden and cognition (2008) (0)
- Automatic image analysis of AV133 PET images (2012) (0)
- CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES (2019) (0)
- Profiling beta-amyloid in the Alzheimer's disease brain (2012) (0)
- LONGITUDINAL EVALUATION OF THE NATURAL HISTORY OF Aβ IN PLASMA AND BRAIN (2019) (0)
- Greater rate of atrophy in elderly with high versus low Aβ deposition (2011) (0)
- P3-620: Increased protein and fibre intake is associated with higher performance in the ABIL PACC score in cognitively normal adults: Australian imaging, biomarkers and lifestyle (ABIL) study (2006) (0)
- Quantitative thresholds for 18 F‐florbetaben PET for the detection of low amyloid load: Neuroimaging / Optimal neuroimaging measures for early detection (2020) (0)
- TAU AND Aβ-AMYLOID IMAGING IN NIEMANN-PICK TYPE C (2017) (0)
- Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods (2021) (0)
- PET tau imaging in Alzheimer's disease using novel 18F-labeled 2-phenylquinoline derivatives (2013) (0)
- Rates of hippocampal atrophy are associated with increased PiB-PET amyloid load in elderly controls (2012) (0)
- Early-Phase F-18-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neurodegeneration (2019) (0)
- TAU, Aβ-AMYLOID, AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN VIETNAM WAR VETERANS (2017) (0)
- Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods (2021) (0)
- 18 F‐PI‐2620 tau‐PET in corticobasal syndrome (ActiGliA cohort): Neuroimaging: Other neurodegenerative disorders (2020) (0)
- Longitudinal evaluation of basal forebrain atrophy and its association with beta-amyloid burden and hippocampal volume in Alzheimer's disease (2013) (0)
- Amyloid-beta remains a membrane peptide after cleavage. implications for secretion and kinetics of abeta turnover in human brain (2015) (0)
- A Machine Learning Approach for Computer-Aided Detection of Cerebral Microbleed Using High-order Shape Features (2014) (0)
- Beta-amyloid and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease (2013) (0)
- Investigating Alzheimer's disease in the blood cellular fraction (2011) (0)
- JAMA Paper supplement (2015) (0)
- Rates of hippocampal atrophy are associated with increased PiB-PET amyloid load in elderly controls (2012) (0)
- P3-469 FREE AND CUED SELECTIVE REMINDING TEST PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE IN PEOPLE WITH MILD COGNITIVE IMPAIRMENT (2018) (0)
- In vivo imaging of brain proteinopathies (2018) (0)
- 1.[Invited keynote lecture] The Tao of Tau: implications for in vivo tau imaging (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Victor L. L. Villemagne?
Victor L. L. Villemagne is affiliated with the following schools: